Wednesday, July 8, 2026

biotech · Dystrophic Epidermolysis Bullosa · Autosomal Recessive Ichthyosis · KRYS

Krystal Biotech Netherlands

Krystal Biotech Netherlands clinical programs — 14 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, US HQ
2016 Founded
306 Employees
Public company Type
KRYS · NYSE Ticker
Company details
Status
Public
HQ
2100 Wharton Street, Suite 701, Pittsburgh, PA 15203, US
Founded
2016
Employees
306
Programs
14
Drugs
7
Patents
14
Intelligence · Clinical Programs

Krystal Biotech Netherlands projects

14 ClinicalTrials.gov programs sponsored by Krystal Biotech Netherlands.

Krystal Biotech Netherlands has 14 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. KB803

    Krystal Biotech Netherlands B.V.

    Dystrophic Epidermolysis Bullosa

    phase 3 mab active

    1 trial
  2. Open Label Topical Beremagene Geperpavec (B-VEC)

    Krystal Biotech Netherlands B.V.

    Dystrophic Epidermolysis Bullosa

    phase 3 mab completed

    1 trial
  3. Topical Beremagene Geperpavec

    Krystal Biotech Netherlands B.V.

    Dystrophic Epidermolysis Bullosa

    phase 3 mab completed

    2 trials
  4. KB105

    Krystal Biotech Netherlands B.V.

    Autosomal Recessive Ichthyosis

    phase 2 mab active

    1 trial
  5. KB105

    Krystal Biotech Netherlands B.V.

    TGM-1 Related Autosomal Recessive Congenital Ichthyosis

    phase 2 mab active

    1 trial
  6. KB304

    Krystal Biotech Netherlands B.V.

    Wrinkles in Decolletage

    phase 2 mab active

    1 trial
  7. KB707

    Krystal Biotech Netherlands B.V.

    Cancer

    phase 2 mab active

    1 trial
  8. KB707

    Krystal Biotech Netherlands B.V.

    Lung Cancer, Non-small Cell

    phase 2 mab active

    1 trial
  9. KB801

    Krystal Biotech Netherlands B.V.

    Neurotrophic Keratitis

    phase 2 mab active

    1 trial
  10. Mebendazole

    Krystal Biotech Netherlands B.V.

    Pilomyxoid Astrocytoma

    phase 2 small molecule completed

    1 trial
  11. KB301

    Krystal Biotech Netherlands B.V.

    Skin Roughness

    phase 1 mab active

    1 trial
  12. KB407 (Nebulization)

    Krystal Biotech Netherlands B.V.

    Cystic Fibrosis

    phase 1 mab active

    2 trials
  13. KB408 (Nebulization)

    Krystal Biotech Netherlands B.V.

    Alpha 1-Antitrypsin Deficiency

    phase 1 small molecule active

    1 trial
  14. LY2456302

    Krystal Biotech Netherlands B.V.

    Anxiety Disorders

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Krystal Biotech Netherlands have?

14 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.